FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 342:894-895 March 23, 2000 Number 12 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Herwaldt, B. L. Related Article by Jha, T.K. PubMed Citation

To the Editor: The results reported by Jha et al. (Dec. 9 issue)¹ on the use of miltefosine, the long-awaited therapy for visceral leishmaniasis, are convincing and possibly open a new avenue for the treatment of protozoan diseases.

My colleagues and I have described the use of alkylphosphocholines as a completely new approach to antitumor and antileishmanial therapy.^2,3 The chemical description and the chemical structure of the molecule provided by Jha et al. are wrong. They state that "miltefosine, a close analogue of lecithin (phosphatidylcholine) in which phosphorylcholine is attached by an ether bond rather than an ester bond to . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Kondapaka, S. B., Singh, S. S., Dasmahapatra, G. P., Sausville, E. A., Roy, K. K. (2003). Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Molecular Cancer Therapeutics 2: 1093-1103 [Abstract] [Full Text]